Results 131 to 140 of about 1,410,232 (284)

Gut microbiota as a novel therapeutic target for eating disorders and obesity

open access: yesBritish Journal of Pharmacology, EarlyView.
The graphical abstract highlights the bidirectional interaction between the gut microbiota and central homeostatic and hedonic mechanisms regulating food intake, which contributes to overweight and obesity. It also illustrates emerging microbiota‐based biomarkers and therapeutic strategies (including prebiotics, probiotics, postbiotics, synbiotics and ...
Solveiga Samulėnaitė   +5 more
wiley   +1 more source

Re‐thinking peripheral dysfunctions in obesity: The emerging role of sulphaceutics and sulphanutraceutics

open access: yesBritish Journal of Pharmacology, EarlyView.
Obesity is a chronic, relapsing, multisystem disease in which cardiometabolic risk arises from excess adiposity and progressive dysfunction of peripheral organs, ultimately disrupting endocrine and metabolic crosstalk among tissues. Within this network, sulphur‐based biology, centred on hydrogen sulphide and related reactive sulphur species, has ...
Martina Smimmo   +4 more
wiley   +1 more source

Adiponectin Battles Ceramides

open access: yes, 2011
The beneficial effects of adiponectin are mediated through the ceramidase activity of its receptor.
Christoph Buettner
core   +1 more source

Therapeutic access points: The roles of circumventricular organs in drug delivery and metabolic regulation

open access: yesBritish Journal of Pharmacology, EarlyView.
The current obesity drug landscape, dominated by GLP‐1 receptor agonists and emerging multi‐agonist therapies, has reinforced that long‐term weight loss is achieved in large part through central mechanisms that suppress appetite and reshape energy balance.
Ines Martinez‐Corral   +3 more
wiley   +1 more source

Metabolic remodelling in anthracycline cardiotoxicity: mechanisms and therapeutic insights

open access: yesBritish Journal of Pharmacology, EarlyView.
Cardiac metabolic remodelling in anthracycline‐induced cardiomyopathy and metabolically oriented cardioprotective strategies. Schematic representation of substrate utilization, mitochondrial bioenergetic function and metabolic flexibility in the healthy heart, in anthracycline‐induced cardiomyopathy and under potential cardioprotective interventions ...
Giulia Guerra   +5 more
wiley   +1 more source

Additional file 4: of Adiponectin and adiponectin receptor 1 overexpression enhance inflammatory bowel disease

open access: yes, 2018
Figure S3. Mouse ADN bound to porcine AdipoR1 in pAdipoR1 mice. (A) Mouse ADN (mADN) bound with mouse AdipoR1 in wild type (WT) mice, and mADN bound with mouse and flag-conjugated porcine AdipoR1 in pAdipoR1 mice.
Tang-Long Shen (109582)   +5 more
core   +1 more source

International consensus recommendations for identifying malnutrition in children with neurological impairment

open access: yesDevelopmental Medicine &Child Neurology, EarlyView.
Abstract Children with neurological impairment (CNI) are at increased risk of malnutrition because of functional, medical, and socioeconomic challenges. However, difficulties in obtaining reliable anthropometric measurements and differences in body composition limit the usefulness of conventional nutritional indicators.
Sarah Vermilyea   +19 more
wiley   +1 more source

The Effect of Placental Mesenchymal Stem Cells on The Protection of Chronic Renal Failure: The Role of Adiponectin

open access: yesCumhuriyet Science Journal
Chronic glomerular and tubulointerstitial fibrosis represents a major pathological process leading to end-stage renal failure. Mesenchymal stem cell (MSC) therapy has emerged as a promising approach for renal tissue repair.
Ezgi Akan   +4 more
doaj   +1 more source

Reduced Risk of MASLD and Cardiometabolic Disease Following Renal Denervation Therapy in Patients With Resistant Hypertension

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Introduction Autonomic dysfunction increases the risk of cardio‐kidney‐metabolic (CKM) syndrome including metabolic dysfunction‐associated steatotic liver disease (MASLD), type 2 diabetes (T2D), cardiovascular disease (CVD) and chronic kidney disease (CKD).
Alex E. Henney   +8 more
wiley   +1 more source

Safety, Tolerability, Pharmacokinetics and Exploratory Pharmacodynamics of Melanin‐Concentrating Hormone Receptor‐1 Antagonist RGH‐706 in Healthy and Overweight or Obese Men

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim This Phase 1 program evaluated the safety, tolerability, pharmacokinetics and exploratory pharmacodynamics of the novel melanin‐concentrating hormone receptor‐1 antagonist RGH‐706. Methods Study A was a first‐in‐man, randomized trial comprising a double‐blind, placebo‐controlled single‐ascending‐dose part (0.1–162.5 mg) and a two‐way ...
Thomas Brevig   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy